Should I Buy SOLV? SOLV 2026 Analysis

Should You Buy Solventum Corp (SOLV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

76.600

1 Day change

-1.30%

52 Week Range

88.200

Analysis Updated At

2026/01/26

Solventum Corp (SOLV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong financial performance in its latest quarter, positive analyst sentiment with multiple upgrades and increased price targets, and a favorable long-term growth outlook. While technical indicators are neutral to slightly bearish in the short term, the stock's potential for long-term appreciation outweighs these concerns. The lack of recent news or congress trading data does not detract from the positive investment case.

Technical Analysis

The MACD is below zero and negatively expanding (-0.445), indicating bearish momentum. RSI is neutral at 34.063, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 79.005), with resistance at R1: 84.964. Overall, the technical indicators suggest a neutral to slightly bearish short-term outlook.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Strong Q3 financial performance with a 937.70% YoY net income increase and 931.43% YoY EPS growth.
Positive analyst sentiment, including multiple upgrades and increased price targets, with a consensus target of $
Improved long-term cost savings plan and strong execution against guidance.
Favorable dental industry outlook and increased patient volume expectations.

Neutral/Negative Catalysts

Gross margin decreased by 3.40% YoY in Q3
Short-term technical indicators show bearish momentum.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.

Financial Performance

In Q3 2025, Solventum's revenue increased to $2.096 billion (+0.67% YoY), net income surged to $1.266 billion (+937.70% YoY), and EPS rose to $7.22 (+931.43% YoY). However, gross margin dropped to 54.06% (-3.40% YoY). Overall, the company demonstrated exceptional profitability growth despite a slight decline in gross margin.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly positive on Solventum. Mizuho upgraded the stock to Outperform with a $100 price target, citing a strong dental consumable outlook and benefits from the Acera acquisition. BTIG also upgraded the stock to Buy with a $100 target, highlighting reduced debt and compelling valuation. Piper Sandler raised its target to $98, noting consistent outperformance and guidance raises. UBS increased its target to $79, citing strong Q3 results and a long-term cost savings plan.

8 Analyst Rating

Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is 93.71 USD with a low forecast of 79 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

0 Sell

Moderate Buy

Current: 77.610

Low

Averages

93.71

High

105

Current: 77.610

Low

Averages

93.71

High

105

KeyBanc

Sector Weight -> Overweight

upgrade

$97

AI Analysis

2026-01-26

New

Reason

KeyBanc

Price Target

$97

AI Analysis

2026-01-26

New

upgrade

Sector Weight -> Overweight

Reason

KeyBanc last night upgraded Solventum to Overweight from Sector Weight with a $97 price target. The firm says the company's spinoff from 3M "is off to an encouraging start." With new product launches, accretive acquisitions, a "steady" macro backdrop, and the annualization of SKU headwinds in 2027, Solventum could track closer to its 4%-5% organic growth objective ahead of its 2028 timeline, the analyst tells investors in a research note. KeyBanc also likes the stock setup for 2026, saying recent concerns around Solventum's 2026 guidance may be overblown and that the company has shifted into an offensive capital allocation strategy.

KeyBanc

Brett Fishbin

Sector Weight

Overweight

upgrade

$97

2026-01-25

New

Reason

KeyBanc

Brett Fishbin

Price Target

$97

2026-01-25

New

upgrade

Sector Weight

Overweight

Reason

KeyBanc analyst Brett Fishbin upgraded Solventum to Overweight from Sector Weight with a $97 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SOLV

Unlock Now

SOLV Should I Buy

SOLV Should I Buy

Should You Buy Solventum Corp (SOLV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch